Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J asks for Remicade arbitration

This article was originally published in The Tan Sheet

Executive Summary

Johnson & Johnson says the details of Merck's complicated reverse merger with Schering-Plough do not circumvent changing control of a J&J-Schering partnership for a blockbuster rheumatoid arthritis franchise. On May 27, J&J requested an American Arbitration Association ruling that the March 9 Merck-Schering merger agreement constitutes a change of control that would terminate J&J subsidiary Centocor Ortho Biotech's 1998 deal with Schering about rheumatoid arthritis drug Remicade (infliximab) and the investigational follow-up Simponi (golimumab). Market analysts predicted J&J is capable of making a competing bid for Schering's consumer health business, but the firm was more likely to seek control of the Remicade partnership in response to the $41.1 billion merger agreement (1"The Tan Sheet" March 16, 2009, p. 4). J&J, which currently has U.S. marketing rights to the anti-TNFs, seeks Schering's marketing rights outside the U.S., excluding Japan and some Asian markets

You may also be interested in...



J&J Options In Face Of Merck’s Schering Bid Include OTC Deal

One option for Johnson & Johnson in response to Merck's bid for Schering-Plough is to make a deal for the latter's consumer health business

Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker

Vaccination Health Next Stop For Dentovations’ Self+ Immunity Supplement Line

Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.

Topics

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel